You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Verogen will gain access to GEDmatch's database of genetic profiles, although users can choose whether law enforcement can search their data to solve violent crimes.
The company said it will use the funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
Researchers demonstrated the importance of integrating mutational and transcriptomic profiles to improve understanding of AML and MDS patients' prognosis.
The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.
The partnership is intended to add new assays to the NeuMoDx MDx menu, including tests for post-transplant infections, pharmacogenetics applications, and others.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
A group of researchers devised a DNA-based storage system that uses DNA molecules to record data and produces materials with immutable memory.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The firm is offering 24.6 million shares of its common stock and warrants to purchase 24.6 million shares of stocks to financially support and expand its business.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
Last week, GenomeWeb's readers were most interested in Veritas Genetics' decision to halt its US operations.
The new tool can provide a more accurate and unbiased view of the multiple outcomes of CRISPR-based gene editing, according to the developers.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
The center is responsible for developing and maintaining the technical platforms by which people participate in and engage with the program.
News items for the week of Dec. 2, 2019.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The researchers profiled 44 cancer-related genes in 191 individuals with familial breast cancer, colorectal cancer, or other forms of early-onset cancer.
Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.
Germany's Life & Brain Genomics hopes to streamline sample management and genetic array input for its multi-omics analysis services.
Using systems biology, investigators put cancer risk SNPs in a network context, identifying immune, tumor-related, and other genes influenced by the variants in multiple tissue types.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.